利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

7864 条记录 (耗时 0.062 秒)

    HUMAN ORIGIN PROBIOTIC LACTOBACILIUS RHAMNOSUS HL-200 TO REDUCE LEAKY GUT BY METABOLIZING ETHANOLAMINE
    1.
    发明申请
    HUMAN ORIGIN PROBIOTIC LACTOBACILIUS RHAMNOSUS HL-200 TO REDUCE LEAKY GUT BY METABOLIZING ETHANOLAMINE 有权

    公开(公告)号：US20230131140A1

    公开(公告)日：2023-04-27

    申请号：US17973909

    申请日：2022-10-26

    申请人： University of South Florida

    发明人： Hariom Yadav ,  Shalinie Jain ,  Sidharth Mishra

    IPC分类号： A61K35/747 ,  A61K45/06 ,  A61P1/00

    摘要： The present disclosure provides for a method of treating increased gut permeability, including administering a therapeutically effective amount of a human-derived probiotic to a patient in need thereof. Further provided herein is a method of increasing a patient's metabolism of ethanolamine, including administering a therapeutically effective amount of human derived probiotics to the patient in need thereof. Also provided herein is a pharmaceutical composition, including a first strain of Lactobacillus and a second probiotic strain. The present disclosure also provides for a pharmaceutical composition, including Lactobacillus and an antidiabetic drug. Additionally, provided herein is a pharmaceutical composition, including Lactobacillus and a weight management drug.

    PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER CONTAINING, AS ACTIVE INGREDIENT, COMPLEX OF BIGUANIDE-BASED COMPOUND AND FLAVONE, HYDROXYFLAVONE, FLAVANONE, FLAVONE DERIVATIVE, HYDROXYFLAVONE DERIVATIVE, OR FLAVANONE DERIVATIVE
    3.
    发明申请
    PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER CONTAINING, AS ACTIVE INGREDIENT, COMPLEX OF BIGUANIDE-BASED COMPOUND AND FLAVONE, HYDROXYFLAVONE, FLAVANONE, FLAVONE DERIVATIVE, HYDROXYFLAVONE DERIVATIVE, OR FLAVANONE DERIVATIVE 有权

    公开(公告)号：US20230119060A1

    公开(公告)日：2023-04-20

    申请号：US17905541

    申请日：2020-08-20

    申请人： FRONTBIO INC.

    发明人： Jae Yong LEE ,  Hong Won SUH ,  Soon Sung LIM ,  Madhuri Rame-Shwar SHENDE

    IPC分类号： A61K31/155 ,  A61K31/352 ,  A61K31/7048 ,  A61P35/00 ,  A61P1/00 ,  A61P11/00 ,  A61P13/08 ,  A61P1/18

    摘要： The present invention relates to a pharmaceutical composition for prevention or treatment of cancer, containing a complex, mixed or combined preparation of a biguanide-based compound or a pharmaceutically acceptable salt thereof; and a flavone, a hydroxyflavone, a flavanone, a flavone derivative, a hydroxyflavone derivative, a flavanone derivative or a pharmaceutically acceptable salt thereof as an active ingredient. It has been confirmed that a significantly higher synergistic anticancer activity is exhibited in a case where the complex, mixed or combined preparation of a biguanide-based compound or a pharmaceutically acceptable salt thereof; and a flavone, a hydroxyflavone, a flavanone, a flavone derivative, a hydroxyflavone derivative, a flavanone derivative or a pharmaceutically acceptable salt thereof is administered compared to a case where the biguanide-based compound or a pharmaceutically acceptable salt thereof; and the flavone, hydroxyflavone, flavanone, flavone derivative, hydroxyflavone derivative, flavanone derivative or a pharmaceutically acceptable salt thereof are each administered singly. Consequently, the pharmaceutical composition containing a biguanide-based compound or a pharmaceutically acceptable salt thereof; and a flavone, a hydroxyflavone, a flavanone, a flavone derivative, a hydroxyflavone derivative, a flavanone derivative or a pharmaceutically acceptable salt thereof in a complex, mixed or combined manner according to the present invention can be usefully utilized for the prevention or treatment of cancer.